{
    "nctId": "NCT00082277",
    "briefTitle": "Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer",
    "officialTitle": "A Multicentre Phase III/IV Study, of the Effects of Risedronate Sodium (ACTONEL\u2122, 35mg/Week, Oral) on Bone, in Postmenopausal Women, With Hormone-receptor-positive Early Breast Cancer, Treated With Anastrozole (ARIMIDEX\u2122, 1mg/Day Oral) With Risk of Fragility Fracture (High-risk Fragility Fracture-open-label, Non-comparative Stratum; Moderate-risk of Fragility Fracture-randomised, Double-blind Stratum; Low-risk of Fragility Fracture - Open-label, Non-comparative Stratum)Abbreviated",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 237,
    "primaryOutcomeMeasure": "The change from baseline in lumbar spine (L1-L4) bone mineral density (BMD)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women defined as Postmenopausal\n* Histologically proven operable invasive breast cancer\n* Hormone-receptor-positive breast cancer\n\nExclusion Criteria:\n\n* Clinical evidence of metastatic disease\n* Bilateral hip fractures or bilateral hip prosthesis\n* Receiving or received in last 12 months hormonal therapy for breast cancer, bisphosphonate therapy, oestrogens\n* Malabsorption syndrome",
    "sex": "FEMALE",
    "minimumAge": "55 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}